Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
86
CHGCY Quote, Financials, Valuation and Earnings
Last price:
$32.11
Seasonality move
:
1.13%
Day range:
$30.73 - $33.23
52-week range:
$19.50 - $33.23
Dividend yield:
0%
P/E ratio:
36.47x
P/S ratio:
12.57x
P/B ratio:
8.18x
Volume:
379.7K
Avg. volume:
163.7K
1-year change:
31.49%
Market cap:
$105.7B
Revenue:
$8.4B
EPS (TTM):
$0.88
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CHGCY
Chugai Pharmaceutical Co., Ltd.
|
-- | -- | -- | -- | -- |
|
AMGXF
AnGes, Inc.
|
-- | -- | -- | -- | -- |
|
HLOSF
Healios KK
|
-- | -- | -- | -- | -- |
|
PPTDF
PeptiDream Inc.
|
-- | -- | -- | -- | -- |
|
SOLTF
Nxera Pharma Co., Ltd.
|
-- | -- | -- | -- | -- |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CHGCY
Chugai Pharmaceutical Co., Ltd.
|
$32.11 | -- | $105.7B | 36.47x | $0.19 | 0% | 12.57x |
|
AMGXF
AnGes, Inc.
|
$0.36 | -- | $139.1M | -- | $0.00 | 0% | 20.32x |
|
HLOSF
Healios KK
|
$2.10 | -- | $243M | -- | $0.00 | 0% | 308.70x |
|
PPTDF
PeptiDream Inc.
|
$8.85 | -- | $1.1B | 13.79x | $0.00 | 0% | 9.26x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$5.44 | -- | $492.3M | -- | $0.00 | 0% | 2.47x |
|
STMM
Stemcell Holdings, Inc.
|
$0.06 | -- | $60M | -- | $0.00 | 0% | 0.17x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CHGCY
Chugai Pharmaceutical Co., Ltd.
|
-- | -0.916 | -- | 3.46x |
|
AMGXF
AnGes, Inc.
|
1.74% | 0.000 | 0.25% | 0.89x |
|
HLOSF
Healios KK
|
34.82% | -0.193 | 7.46% | 1.83x |
|
PPTDF
PeptiDream Inc.
|
24.85% | 0.074 | 6.74% | 1.48x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
48.47% | 1.070 | 73.82% | 1.61x |
|
STMM
Stemcell Holdings, Inc.
|
-- | 0.000 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CHGCY
Chugai Pharmaceutical Co., Ltd.
|
$1.7B | $1.1B | 22.41% | 22.53% | 48.92% | $627.3M |
|
AMGXF
AnGes, Inc.
|
$399.5K | -$10.4M | -153.93% | -162.7% | -703% | -- |
|
HLOSF
Healios KK
|
-$798.3K | -$6.6M | -44.36% | -88.96% | -4043.07% | -$5.3M |
|
PPTDF
PeptiDream Inc.
|
$17.4M | -$6M | -5.23% | -7.06% | -16.33% | -$2.4M |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$37.1M | -$8.9M | -9.66% | -19.06% | -17.59% | -$1M |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- | -- |
Chugai Pharmaceutical Co., Ltd. vs. Competitors
-
Which has Higher Returns CHGCY or AMGXF?
AnGes, Inc. has a net margin of 37.08% compared to Chugai Pharmaceutical Co., Ltd.'s net margin of -190.55%. Chugai Pharmaceutical Co., Ltd.'s return on equity of 22.53% beat AnGes, Inc.'s return on equity of -162.7%.
Company Gross Margin Earnings Per Share Invested Capital CHGCYChugai Pharmaceutical Co., Ltd.74.72% $0.25 $12.9B AMGXFAnGes, Inc.27% -$0.01 $20M -
What do Analysts Say About CHGCY or AMGXF?
Chugai Pharmaceutical Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand AnGes, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Chugai Pharmaceutical Co., Ltd. has higher upside potential than AnGes, Inc., analysts believe Chugai Pharmaceutical Co., Ltd. is more attractive than AnGes, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CHGCYChugai Pharmaceutical Co., Ltd.0 0 0 AMGXFAnGes, Inc.0 0 0 -
Is CHGCY or AMGXF More Risky?
Chugai Pharmaceutical Co., Ltd. has a beta of 0.549, which suggesting that the stock is 45.062% less volatile than S&P 500. In comparison AnGes, Inc. has a beta of 0.068, suggesting its less volatile than the S&P 500 by 93.218%.
-
Which is a Better Dividend Stock CHGCY or AMGXF?
Chugai Pharmaceutical Co., Ltd. has a quarterly dividend of $0.19 per share corresponding to a yield of 0%. AnGes, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chugai Pharmaceutical Co., Ltd. pays 79.47% of its earnings as a dividend. AnGes, Inc. pays out -- of its earnings as a dividend. Chugai Pharmaceutical Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CHGCY or AMGXF?
Chugai Pharmaceutical Co., Ltd. quarterly revenues are $2.2B, which are larger than AnGes, Inc. quarterly revenues of $1.5M. Chugai Pharmaceutical Co., Ltd.'s net income of $833.4M is higher than AnGes, Inc.'s net income of -$2.8M. Notably, Chugai Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 36.47x while AnGes, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chugai Pharmaceutical Co., Ltd. is 12.57x versus 20.32x for AnGes, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CHGCYChugai Pharmaceutical Co., Ltd.12.57x 36.47x $2.2B $833.4M AMGXFAnGes, Inc.20.32x -- $1.5M -$2.8M
-
Which has Higher Returns CHGCY or HLOSF?
Healios KK has a net margin of 37.08% compared to Chugai Pharmaceutical Co., Ltd.'s net margin of -9751.87%. Chugai Pharmaceutical Co., Ltd.'s return on equity of 22.53% beat Healios KK's return on equity of -88.96%.
Company Gross Margin Earnings Per Share Invested Capital CHGCYChugai Pharmaceutical Co., Ltd.74.72% $0.25 $12.9B HLOSFHealios KK-491.87% $0.12 $47.9M -
What do Analysts Say About CHGCY or HLOSF?
Chugai Pharmaceutical Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that Chugai Pharmaceutical Co., Ltd. has higher upside potential than Healios KK, analysts believe Chugai Pharmaceutical Co., Ltd. is more attractive than Healios KK.
Company Buy Ratings Hold Ratings Sell Ratings CHGCYChugai Pharmaceutical Co., Ltd.0 0 0 HLOSFHealios KK0 0 0 -
Is CHGCY or HLOSF More Risky?
Chugai Pharmaceutical Co., Ltd. has a beta of 0.549, which suggesting that the stock is 45.062% less volatile than S&P 500. In comparison Healios KK has a beta of 0.262, suggesting its less volatile than the S&P 500 by 73.819%.
-
Which is a Better Dividend Stock CHGCY or HLOSF?
Chugai Pharmaceutical Co., Ltd. has a quarterly dividend of $0.19 per share corresponding to a yield of 0%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chugai Pharmaceutical Co., Ltd. pays 79.47% of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend. Chugai Pharmaceutical Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CHGCY or HLOSF?
Chugai Pharmaceutical Co., Ltd. quarterly revenues are $2.2B, which are larger than Healios KK quarterly revenues of $162.3K. Chugai Pharmaceutical Co., Ltd.'s net income of $833.4M is higher than Healios KK's net income of $12.4M. Notably, Chugai Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 36.47x while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chugai Pharmaceutical Co., Ltd. is 12.57x versus 308.70x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CHGCYChugai Pharmaceutical Co., Ltd.12.57x 36.47x $2.2B $833.4M HLOSFHealios KK308.70x -- $162.3K $12.4M
-
Which has Higher Returns CHGCY or PPTDF?
PeptiDream Inc. has a net margin of 37.08% compared to Chugai Pharmaceutical Co., Ltd.'s net margin of -9.39%. Chugai Pharmaceutical Co., Ltd.'s return on equity of 22.53% beat PeptiDream Inc.'s return on equity of -7.06%.
Company Gross Margin Earnings Per Share Invested Capital CHGCYChugai Pharmaceutical Co., Ltd.74.72% $0.25 $12.9B PPTDFPeptiDream Inc.47.44% -$0.03 $437.5M -
What do Analysts Say About CHGCY or PPTDF?
Chugai Pharmaceutical Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Chugai Pharmaceutical Co., Ltd. has higher upside potential than PeptiDream Inc., analysts believe Chugai Pharmaceutical Co., Ltd. is more attractive than PeptiDream Inc..
Company Buy Ratings Hold Ratings Sell Ratings CHGCYChugai Pharmaceutical Co., Ltd.0 0 0 PPTDFPeptiDream Inc.0 0 0 -
Is CHGCY or PPTDF More Risky?
Chugai Pharmaceutical Co., Ltd. has a beta of 0.549, which suggesting that the stock is 45.062% less volatile than S&P 500. In comparison PeptiDream Inc. has a beta of 0.573, suggesting its less volatile than the S&P 500 by 42.666%.
-
Which is a Better Dividend Stock CHGCY or PPTDF?
Chugai Pharmaceutical Co., Ltd. has a quarterly dividend of $0.19 per share corresponding to a yield of 0%. PeptiDream Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chugai Pharmaceutical Co., Ltd. pays 79.47% of its earnings as a dividend. PeptiDream Inc. pays out -- of its earnings as a dividend. Chugai Pharmaceutical Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CHGCY or PPTDF?
Chugai Pharmaceutical Co., Ltd. quarterly revenues are $2.2B, which are larger than PeptiDream Inc. quarterly revenues of $36.8M. Chugai Pharmaceutical Co., Ltd.'s net income of $833.4M is higher than PeptiDream Inc.'s net income of -$3.5M. Notably, Chugai Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 36.47x while PeptiDream Inc.'s PE ratio is 13.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chugai Pharmaceutical Co., Ltd. is 12.57x versus 9.26x for PeptiDream Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CHGCYChugai Pharmaceutical Co., Ltd.12.57x 36.47x $2.2B $833.4M PPTDFPeptiDream Inc.9.26x 13.79x $36.8M -$3.5M
-
Which has Higher Returns CHGCY or SOLTF?
Nxera Pharma Co., Ltd. has a net margin of 37.08% compared to Chugai Pharmaceutical Co., Ltd.'s net margin of -99.41%. Chugai Pharmaceutical Co., Ltd.'s return on equity of 22.53% beat Nxera Pharma Co., Ltd.'s return on equity of -19.06%.
Company Gross Margin Earnings Per Share Invested Capital CHGCYChugai Pharmaceutical Co., Ltd.74.72% $0.25 $12.9B SOLTFNxera Pharma Co., Ltd.73.58% -$0.55 $755.2M -
What do Analysts Say About CHGCY or SOLTF?
Chugai Pharmaceutical Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma Co., Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Chugai Pharmaceutical Co., Ltd. has higher upside potential than Nxera Pharma Co., Ltd., analysts believe Chugai Pharmaceutical Co., Ltd. is more attractive than Nxera Pharma Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CHGCYChugai Pharmaceutical Co., Ltd.0 0 0 SOLTFNxera Pharma Co., Ltd.0 0 0 -
Is CHGCY or SOLTF More Risky?
Chugai Pharmaceutical Co., Ltd. has a beta of 0.549, which suggesting that the stock is 45.062% less volatile than S&P 500. In comparison Nxera Pharma Co., Ltd. has a beta of 0.018, suggesting its less volatile than the S&P 500 by 98.16%.
-
Which is a Better Dividend Stock CHGCY or SOLTF?
Chugai Pharmaceutical Co., Ltd. has a quarterly dividend of $0.19 per share corresponding to a yield of 0%. Nxera Pharma Co., Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chugai Pharmaceutical Co., Ltd. pays 79.47% of its earnings as a dividend. Nxera Pharma Co., Ltd. pays out -- of its earnings as a dividend. Chugai Pharmaceutical Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CHGCY or SOLTF?
Chugai Pharmaceutical Co., Ltd. quarterly revenues are $2.2B, which are larger than Nxera Pharma Co., Ltd. quarterly revenues of $50.4M. Chugai Pharmaceutical Co., Ltd.'s net income of $833.4M is higher than Nxera Pharma Co., Ltd.'s net income of -$50.1M. Notably, Chugai Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 36.47x while Nxera Pharma Co., Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chugai Pharmaceutical Co., Ltd. is 12.57x versus 2.47x for Nxera Pharma Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CHGCYChugai Pharmaceutical Co., Ltd.12.57x 36.47x $2.2B $833.4M SOLTFNxera Pharma Co., Ltd.2.47x -- $50.4M -$50.1M
-
Which has Higher Returns CHGCY or STMM?
Stemcell Holdings, Inc. has a net margin of 37.08% compared to Chugai Pharmaceutical Co., Ltd.'s net margin of --. Chugai Pharmaceutical Co., Ltd.'s return on equity of 22.53% beat Stemcell Holdings, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CHGCYChugai Pharmaceutical Co., Ltd.74.72% $0.25 $12.9B STMMStemcell Holdings, Inc.-- -- -- -
What do Analysts Say About CHGCY or STMM?
Chugai Pharmaceutical Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Stemcell Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Chugai Pharmaceutical Co., Ltd. has higher upside potential than Stemcell Holdings, Inc., analysts believe Chugai Pharmaceutical Co., Ltd. is more attractive than Stemcell Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CHGCYChugai Pharmaceutical Co., Ltd.0 0 0 STMMStemcell Holdings, Inc.0 0 0 -
Is CHGCY or STMM More Risky?
Chugai Pharmaceutical Co., Ltd. has a beta of 0.549, which suggesting that the stock is 45.062% less volatile than S&P 500. In comparison Stemcell Holdings, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock CHGCY or STMM?
Chugai Pharmaceutical Co., Ltd. has a quarterly dividend of $0.19 per share corresponding to a yield of 0%. Stemcell Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chugai Pharmaceutical Co., Ltd. pays 79.47% of its earnings as a dividend. Stemcell Holdings, Inc. pays out -- of its earnings as a dividend. Chugai Pharmaceutical Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CHGCY or STMM?
Chugai Pharmaceutical Co., Ltd. quarterly revenues are $2.2B, which are larger than Stemcell Holdings, Inc. quarterly revenues of --. Chugai Pharmaceutical Co., Ltd.'s net income of $833.4M is higher than Stemcell Holdings, Inc.'s net income of --. Notably, Chugai Pharmaceutical Co., Ltd.'s price-to-earnings ratio is 36.47x while Stemcell Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chugai Pharmaceutical Co., Ltd. is 12.57x versus 0.17x for Stemcell Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CHGCYChugai Pharmaceutical Co., Ltd.12.57x 36.47x $2.2B $833.4M STMMStemcell Holdings, Inc.0.17x -- -- --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
77
RNG alert for Feb 21
RingCentral, Inc. [RNG] is up 34.37% over the past day.
Sell
9
FROG alert for Feb 21
JFrog Ltd. [FROG] is down 24.98% over the past day.
Buy
72
SNSE alert for Feb 21
Sensei Biotherapeutics, Inc. [SNSE] is up 23.81% over the past day.
